全身麻醉药物市场机会、成长动力、产业趋势分析与预测 2025 - 2034

2024 年全球全身麻醉药物市场价值为 54 亿美元，预计在 2025 年至 2034 年期间将以 3.6% 的复合年增长率稳步增长。随着全球医疗保健系统的不断进步，人口老化、医疗保健覆盖面的扩大和微创技术的进步推动了手术量的增加，对有效麻醉药物的需求也在上升。麻醉药物配方的创新旨在提高患者安全性和优化恢復时间，进一步推动该市场的成长。

市场的主要参与者专注于广泛的临床研究和开发，以提高麻醉药物的安全性和有效性，确保其能够满足日益增长的外科手术需求。以患者为中心的医疗保健解决方案的推动也推动了对具有快速起效、作用时间短、副作用小等特点的麻醉剂的投资，使其适合于门诊和当日手术。这些发展预计将促进全球市场发展，巩固其在支持外科手术和诊断进步方面的关键作用。

市场涵盖各种药物，包括七氟醚、丙泊酚、右美托咪啶、瑞芬太尼、地氟醚、咪达唑仑、氯胺酮等。其中，丙泊酚在2024年成为领先药物，占27.5%的市占率。丙泊酚因其起效快、作用时间短、恢復平稳而闻名，仍是全身麻醉的首选，尤其是在门诊环境中。丙泊酚具有充分证据的安全性和有效性，加上广泛的监管部门批准，已成为现代麻醉实践的基石。

从应用角度来看，全身麻醉药物市场分为神经外科、心血管外科、骨科和其他外科手术。 2024 年，骨科手术将引领市场，创造 20 亿美元的收入。肌肉骨骼疾病盛行率的不断上升以及关节镜等微创手术技术的日益普及，增加了该领域对全身麻醉的需求。全身麻醉可确保最佳的肌肉放鬆和镇静，这对于此类手术的成功至关重要。随着这些技术变得越来越容易取得，对麻醉药物的需求将持续上升，从而推动整体市场的成长。

预计美国将主导市场，预计到 2034 年其估值将达到 32 亿美元。选择性和紧急性手术的稳定增加凸显了对可靠有效的麻醉药物的需求，确保了患者的安全并促进了该地区市场的持续成长。

目录

第 1 章：方法论与范围

• 市场范围和定义
• 研究设计
  • 研究方法
  • 资料收集方法
• 基础估算与计算
  • 基准年计算
  • 市场估计的主要趋势
• 预测模型
• 初步研究和验证
  • 主要来源
  • 资料探勘来源

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 外科手术量不断增加
    • 麻醉技术的进步
  • 产业陷阱与挑战
    • 不良反应和安全问题
    • 监理与合规挑战
• 成长潜力分析
• 监管格局
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按产品，2021 年至 2034 年

• 主要趋势
• 七氟醚
• 丙泊酚
• 右美托咪啶
• 瑞芬太尼
• 地氟烷
• 咪达唑仑
• 氯胺酮
• 其他药物

第 6 章：市场估计与预测：按管理路线，2021 年至 2034 年

• 主要趋势
• 静脉
• 吸入

第 7 章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 神经外科
• 心血管外科
• 骨科手术
• 其他应用

第 8 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 门诊手术中心
• 专科诊所

第 9 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Abbott Laboratories
• AbbVie
• AstraZeneca plc
• B. Braun Melsungen AG
• Baxter International Inc.
• Eisai Co.
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals
• Hikma Pharmaceuticals
• Novartis AG
• Par Pharmaceutical
• Pfizer
• Piramal Critical Care
• Teva Pharmaceutical Industries
• Viatris

The Global General Anesthesia Drugs Market, valued at USD 5.4 billion in 2024, is poised to grow at a steady CAGR of 3.6% from 2025 to 2034. General anesthesia drugs play an indispensable role in modern medicine, facilitating a controlled, reversible state of unconsciousness essential for a wide array of surgical procedures. As global healthcare systems continue to advance, the demand for effective anesthesia drugs is rising alongside increased surgical volumes, driven by aging populations, expanding healthcare access, and advancements in minimally invasive techniques. Innovations in anesthesia drug formulations, designed to enhance patient safety and optimize recovery times, further fuel this market's growth.

Key players in the market focus on extensive clinical research and development to improve the safety profiles and efficacy of anesthesia drugs, ensuring their readiness to meet the growing surgical demand. The push for patient-centric healthcare solutions also drives investments in anesthetics that offer rapid onset, short duration of action, and minimal side effects, making them suitable for outpatient and same-day procedures. These developments are expected to bolster the global market, cementing its critical role in supporting surgical and diagnostic advancements.

The market encompasses various drugs, including sevoflurane, propofol, dexmedetomidine, remifentanil, desflurane, midazolam, ketamine, and others. Among these, propofol emerged as the leading drug in 2024, capturing 27.5% of the market share. Renowned for its rapid onset, short duration of action, and smooth recovery profile, propofol remains a preferred choice for general anesthesia, particularly in outpatient settings. Its well-documented safety and efficacy, coupled with widespread regulatory approvals, have established propofol as a cornerstone in modern anesthetic practices.

From an application perspective, the general anesthesia drugs market is segmented into neurological, cardiovascular, orthopedic, and other surgeries. Orthopedic surgeries led the market in 2024, generating USD 2 billion in revenue. The rising prevalence of musculoskeletal disorders and the increasing adoption of minimally invasive surgical techniques, such as arthroscopy, have heightened the demand for general anesthesia in this segment. General anesthesia ensures optimal muscle relaxation and sedation, which are critical for the success of such procedures. As these techniques become more accessible, the demand for anesthesia drugs will continue to rise, driving overall market growth.

The United States is expected to dominate the market, with projections indicating a valuation of USD 3.2 billion by 2034. This expansion is fueled by the growing number of complex and routine surgeries across specialties like cardiovascular, neurological, and orthopedic disciplines. The steady increase in both elective and emergency surgical procedures underscores the need for reliable and effective anesthesia drugs, ensuring patient safety and contributing to the sustained growth of the market in this region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing volume of surgical procedures
    • 3.2.1.2 Advancements in anesthesia technology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Regulatory and compliance challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Sevoflurane
• 5.3 Propofol
• 5.4 Dexmedetomidine
• 5.5 Remifentanil
• 5.6 Desflurane
• 5.7 Midazolam
• 5.8 Ketamine
• 5.9 Other drugs

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Intravenous
• 6.3 Inhalational

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Neurological surgery
• 7.3 Cardiovascular surgery
• 7.4 Orthopedic surgery
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers
• 8.4 Specialty clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie
• 10.3 AstraZeneca plc
• 10.4 B. Braun Melsungen AG
• 10.5 Baxter International Inc.
• 10.6 Eisai Co.
• 10.7 Fresenius SE & Co. KGaA
• 10.8 Hikma Pharmaceuticals
• 10.9 Hikma Pharmaceuticals
• 10.10 Novartis AG
• 10.11 Par Pharmaceutical
• 10.12 Pfizer
• 10.13 Piramal Critical Care
• 10.14 Teva Pharmaceutical Industries
• 10.15 Viatris